Scientist puts microcentrifuge tubes into centrifuge for phase separation. Metabolomic and lipidomic analysis in the analytical chemistry laboratory. | Image Credit: © vladim_ka - stock.adobe.com

A recent lipidomic study explored how 3-methyl-1-p-tolytriazene (MTT) can be an alternative solution when conducting quantitative phospholipid (PL) methylation.
A recent study out of McMaster University in Canada advances lipidomic research by introducing a new approach that aids our understanding of the human lipidome. Lead author Philip Britz-McKibbin and collaborators introduced a derivatization protocol utilizing 3-methyl-1-p-tolyltriazene (MTT), heralding a safer and highly efficient alternative to diazomethane for quantitative phospholipid (PL) methylation (1). Their findings were published in Analytical Chemistry, and they reveal how the new protocol advances capillary electrophoresis–mass spectrometry (CE-MS) capabilities beyond aqueous buffer conditions.
Scientist puts microcentrifuge tubes into centrifuge for phase separation. Metabolomic and lipidomic analysis in the analytical chemistry laboratory. | Image Credit: © vladim_ka - stock.adobe.com
Orthogonal separation techniques coupled with high-resolution MS (HRMS) have become essential in navigating the complexities inherent in the human lipidome (1). Despite this, electrophoretic separations have remained largely overlooked in contemporary lipidomics. However, the innovative MTT-based protocol, integrated with multisegment injection–nonaqueous capillary electrophoresis–mass spectrometry (MSI-NACE-MS), promises a paradigm shift (1).
This novel charge-switch derivatization strategy ensures expanded lipidome coverage, particularly benefiting zwitterionic PLs analyzed as cationic phosphate methyl esters. By mitigating isobaric interferences and ion suppression effects, the approach enhances resolution, sensitivity, and throughput, reducing analysis time to approximately 3.5 minutes per sample (1).
Validation of this method involved the analysis of methyl-tert-butyl ether extracts from reference human plasma. Notably, it facilitated a direct comparison of 48 phosphatidylcholine and 27 sphingomyelin species, aligning with findings from an interlaboratory lipidomics harmonization study (1). Moreover, the team demonstrated the potential for plasma PL quantification using NIST SRM-1950 via relative response factor estimation based on reported consensus concentrations (1).
Britz-McKibbin's team fortified their lipid identification by modeling predictable changes in the electrophoretic mobility for cationic PLs in tandem with MS/MS, bolstering the credibility and accuracy of the method (1).
With its enhanced efficiency and safety, this methodology is designed to further aid lipidomic research now and in the future. Proper use of this methodology can help contribute to new discoveries about lipids within the human body.
This article was written with the help of artificial intelligence and has been edited to ensure accuracy and clarity. You can read more about our policy for using AI here.
(1) Ly, R.; Torres, L. C.; Ly, N.; Britz-McKibbin, P.Expanding Lipidomic Coverage in Multisegment Injection–Nonaqueous Capillary Electrophoresis–Mass Spectrometry via a Convenient and Quantitative Methylation Strategy. Anal. Chem. 2023, 95 (48), 17513–17524. DOI: 10.1021/acs.analchem.3c02605
Free Poster: NDSRI Risk Assessment and Trace-Level Analysis of N-Nitrosamines
April 25th 2025With increasing concern over genotoxic nitrosamine contaminants, regulatory bodies like the FDA and EMA have introduced strict guidelines following several high-profile drug recalls. This poster showcases a case study where LGC and Waters developed a UPLC/MS/MS method for quantifying trace levels of N-nitroso-sertraline in sertraline using Waters mass spectrometry and LGC reference standards.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
Using the Carcinogenic Potency Categorisation Approach (CPCA) to Classify N-nitrosamine Impurities
April 25th 2025Learn how to manage nitrosamine impurities in pharmaceuticals with our free infographic. Discover how the CPCA approach establishes acceptable intake limits and guides the selection of NDSRI reference samples. Stay compliant and ensure safety with our ISO-accredited standards.